Xing Jin, Tian Yijun, Ji Wu, Wang Xinying
Department of General Surgery, Jinling Hospital, the First School of Clinical Medicine, Southern Medical University, Guangzhou.
Department of Anesthesia, Obstetrics and Gynecology Hospital of Changchun, Changchun, PR China.
Medicine (Baltimore). 2020 Feb;99(9):e19230. doi: 10.1097/MD.0000000000019230.
Spermatogenesis associated serine rich 2 (SPATS2) has been reported to be dysregulated in few types of cancer; however, no reports have investigated SPATS2 in liver cancer. The aim of the present study was to investigate SPATS2 expression in liver cancer and to analyze its association with the prognosis of liver cancer patients.We examined the differential expression of SPATS2 in liver cancer by exploring The Cancer Genome Atlas (TCGA) database. The diagnostic efficiency of SPATS2 was obtained by Receiver Operating Characteristic (ROC) curve. The Chi-Squared test was used to assess clinical relevance. Survival analysis and Cox regression model were used to detect the effect of SPATS2 on the survival of liver cancer patients. Gene Set Enrichment Analysis (GSEA) was used to identify signaling pathways related to SPATS2 expression.SPATS2 is highly expressed in liver cancer (P < 2.2e-16) and has the high diagnostic ability (AUC = 0.964). Survival analysis showed that patients with high SPATS2 expression have an apparently shorter overall survival (OS, P < .0001) and relapse-free survival (RFS, P < .0001). Cox regression analysis showed that high SPATS2 expression might be an independent risk factor for liver cancer (OS, HR = 2.41, P = .000; RFS, HR = 1.90, P < .001). GSEA analysis identified 3 signaling pathways (Mitotic spindle, G2 M checkpoint, E2F targets) that were enriched in the presence of high SPATS2 expression.SPATS2 expression could be a novel diagnostic and prognostic biomarker in liver cancer.
据报道，精子发生相关富含丝氨酸蛋白2（SPATS2）在少数几种癌症中表达失调；然而，尚无关于SPATS2在肝癌中研究的报道。本研究旨在探究SPATS2在肝癌中的表达情况，并分析其与肝癌患者预后的关系。我们通过探索癌症基因组图谱（TCGA）数据库来检测SPATS2在肝癌中的差异表达。通过受试者工作特征（ROC）曲线获得SPATS2的诊断效率。采用卡方检验评估临床相关性。生存分析和Cox回归模型用于检测SPATS2对肝癌患者生存的影响。基因集富集分析（GSEA）用于识别与SPATS2表达相关的信号通路。SPATS2在肝癌中高表达（P<2.2e-16），且具有较高的诊断能力（AUC=0.964）。生存分析表明，SPATS2高表达的患者总生存期（OS，P<0.0001）和无复发生存期（RFS，P<0.0001）明显较短。Cox回归分析表明，SPATS2高表达可能是肝癌的独立危险因素（OS，HR=2.41，P=0.000；RFS，HR=1.90，P<0.001）。GSEA分析确定了3条在SPATS2高表达时富集的信号通路（有丝分裂纺锤体、G2/M期检查点、E2F靶点）。SPATS2表达可能是肝癌一种新的诊断和预后生物标志物。
